• About us
• Contact

Advertisement

Person › Details

Andreas Bergmann (SphingoTec GmbH)

Bergmann, Andreas (Sphingotec GmbH 201301 Managing Director)

 

	Organisation	SphingoTec GmbH
	Group	SphingoTec (Group)
	Product	cancer test, early detection

Record changed: 2021-11-29

Advertisement

More documents for Andreas Bergmann

• [1] SphingoTec GmbH. (11/29/21). "Press Release: SphingoTec Appoints Jörg Menten to Leadership Team as Chief Commercial Officer to Drive New Business Growth". Hennigsdorf....
• [2] Adrenomed AG. (11/30/20). "Press Release: Adrenomed Closes EUR 22 Million Equity Financing to Accelerate Development of Adrecizumab (HAM8101) and Provides Business Update". Hennigsdorf....
• [3] Sphingotec GmbH. (4/16/20). "Press Release: SphingoTec Expands Leadership Team and Appoints Achim Plum as Managing Director and Chief Commercial Officer". Hennigsdorf....
• [4] Adrenomed AG. (2/21/20). "Press Release: Adrenomed Announces Positive Top-Line AdrenOSS-2 Phase II Results with Adrecizumab in Septic Shock". Hennigsdorf....
• [5] SphingoTec GmbH. (12/16/19). "Press Release: SphingoTec’s Proprietary Biomarker bio-ADM Detects Residual Congestion in Patients with Heart Failure". Hennigsdorf....
• [6] 4Teen4 Pharmaceuticals GmbH. (12/5/19). "Press Release: Biotech Startup 4Teen4 Pharmaceuticals Closes EUR 7 Million Series A Financing". Hennigsdorf....
• [7] Adrenomed AG. (9/26/19). "Press Release: Adrenomed Completes Full Enrollment with 300 Patients in AdrenOSS-2 Trial with Adrecizumab in Septic Shock". Hennigsdorf....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.